Grant: Project Grant - PA: Breast Cancer Research
McGill University
$100,000.00
Chi3L1 (YKL-40) plays a multifaceted role in modulating tumor immune microenvironment during breast cancer progression.
EF 2022-23
Résumé
Immunotherapies that help the immune system fight cancer have been approved for the treatment of various cancers and there is hope that this approach will be effective in treating certain types of breast cancer. For example, triple negative breast cancers (TNBC) are a particularly aggressive form of breast cancer, some of which are infiltrated with immune cells ("immune hot") making them ideal for immune based therapies. However, other classes of TNBC and other subtypes such as HER2, Luminal B and Luminal A breast cancers possess an immunosuppressive tumor microenvironment, in which the anti-tumor properties of immune cells are suppressed ("immune cold"). Thus, one of the major challenges with immunotherapies targeting breast cancer are the "immune cold" tumors, which are resistant to most conventional immunotherapies. Using a genetically engineered mouse models of Luminal B and HER2 breast cancer, we have identified a factor known as Chi3L1 that plays a multifaceted role in metastatic invasion and colonization through the generation of immunosuppressive tumor microenvironment. In this CIHR proposal, we will evaluate whether impairing Chi3L1 function can re-sensitize "immune cold" tumors to various immunotherapy approaches.
Programme
Project Grant - PA: Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
472379
Name
Muller William J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Chi3L1 (YKL-40) plays a multifaceted role in modulating tumor immune microenvironment during breast cancer progression.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Chi3l1; Her2; Luminal B Breast Cancer; Metastasis; Stat3; Tumor Immune Microenvironment; Ylk40
Abstract
Immunotherapies that help the immune system fight cancer have been approved for the treatment of various cancers and there is hope that this approach will be effective in treating certain types of breast cancer. For example, triple negative breast cancers (TNBC) are a particularly aggressive form of breast cancer, some of which are infiltrated with immune cells ("immune hot") making them ideal for immune based therapies. However, other classes of TNBC and other subtypes such as HER2, Luminal B and Luminal A breast cancers possess an immunosuppressive tumor microenvironment, in which the anti-tumor properties of immune cells are suppressed ("immune cold"). Thus, one of the major challenges with immunotherapies targeting breast cancer are the "immune cold" tumors, which are resistant to most conventional immunotherapies. Using a genetically engineered mouse models of Luminal B and HER2 breast cancer, we have identified a factor known as Chi3L1 that plays a multifaceted role in metastatic invasion and colonization through the generation of immunosuppressive tumor microenvironment. In this CIHR proposal, we will evaluate whether impairing Chi3L1 function can re-sensitize "immune cold" tumors to various immunotherapy approaches.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muller, William J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~